Fengting Yan

1.3k total citations
18 papers, 382 citations indexed

About

Fengting Yan is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Fengting Yan has authored 18 papers receiving a total of 382 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in Fengting Yan's work include Cancer-related gene regulation (6 papers), Lymphoma Diagnosis and Treatment (5 papers) and Protein Degradation and Inhibitors (3 papers). Fengting Yan is often cited by papers focused on Cancer-related gene regulation (6 papers), Lymphoma Diagnosis and Treatment (5 papers) and Protein Degradation and Inhibitors (3 papers). Fengting Yan collaborates with scholars based in United States, Italy and Japan. Fengting Yan's co-authors include Robert A. Baiocchi, Saı̈d Sif, Sookil Tae, Rosa Lapalombella, Natarajan Muthusamy, Lapo Alinari, Gerald V. Denis, Gregory A. Otterson, Leona W. Ayers and Claudio Agostinelli and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Fengting Yan

17 papers receiving 376 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fengting Yan United States 8 259 86 66 49 48 18 382
Stéphanie Sungalee Switzerland 7 286 1.1× 89 1.0× 93 1.4× 58 1.2× 89 1.9× 7 413
Zhongliang Ma China 10 205 0.8× 129 1.5× 98 1.5× 32 0.7× 66 1.4× 16 348
Angelique M. Leonhart Netherlands 8 184 0.7× 165 1.9× 91 1.4× 33 0.7× 50 1.0× 9 349
Francesca Pia Caruso Italy 10 155 0.6× 101 1.2× 90 1.4× 72 1.5× 14 0.3× 19 281
Kieren D. Marini Australia 8 229 0.9× 118 1.4× 80 1.2× 36 0.7× 42 0.9× 9 330
Elena Battistello Switzerland 6 234 0.9× 98 1.1× 115 1.7× 56 1.1× 51 1.1× 7 358
Helen Jiang Canada 5 299 1.2× 128 1.5× 60 0.9× 36 0.7× 36 0.8× 8 378
Danielle N. Yarde United States 8 232 0.9× 140 1.6× 47 0.7× 65 1.3× 25 0.5× 11 386
Lilia Merida de Long Australia 9 225 0.9× 115 1.3× 69 1.0× 21 0.4× 34 0.7× 16 317
Salma Parvin United States 8 154 0.6× 114 1.3× 63 1.0× 56 1.1× 45 0.9× 15 259

Countries citing papers authored by Fengting Yan

Since Specialization
Citations

This map shows the geographic impact of Fengting Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fengting Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fengting Yan more than expected).

Fields of papers citing papers by Fengting Yan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fengting Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fengting Yan. The network helps show where Fengting Yan may publish in the future.

Co-authorship network of co-authors of Fengting Yan

This figure shows the co-authorship network connecting the top 25 collaborators of Fengting Yan. A scholar is included among the top collaborators of Fengting Yan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fengting Yan. Fengting Yan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
LoRusso, Patricia, Toru Mukohara, David Sommerhalder, et al.. (2025). Dose optimization of PF-07248144, a first-in-class KAT6 inhibitor, in patients (pts) with ER+/HER2− metastatic breast cancer (mBC): Results from phase 1 study to support the recommended phase 3 dose (RP3D).. Journal of Clinical Oncology. 43(16_suppl). 1020–1020. 1 indexed citations
2.
Mahtani, Reshma, et al.. (2024). Expanding treatment options for patients with HER2+ metastatic breast cancer with margetuximab plus chemotherapy: a case report series. Frontiers in Oncology. 14. 1419246–1419246. 1 indexed citations
3.
Peterson, Lanell M., Brenda F. Kurland, Fengting Yan, et al.. (2020). 18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2− Metastatic Breast Cancer. Journal of Nuclear Medicine. 62(2). 184–190. 26 indexed citations
4.
Haverkos, Bradley M., Ludmila Katherine Martin, Mark Lustberg, et al.. (2018). Complete and Durable Responses in Primary Central Nervous System Posttransplant Lymphoproliferative Disorder with Zidovudine, Ganciclovir, Rituximab, and Dexamethasone. Clinical Cancer Research. 24(14). 3273–3281. 16 indexed citations
5.
Yan, Fengting, Ajay K. Gopal, & Solomon A. Graf. (2017). Targeted Drugs as Maintenance Therapy after Autologous Stem Cell Transplantation in Patients with Mantle Cell Lymphoma. Pharmaceuticals. 10(1). 28–28. 1 indexed citations
6.
Haverkos, Bradley M., Ludmila Katherine Martin, Mark Lustberg, et al.. (2014). Epstein-Barr Virus Kinase-Targeted Therapy for Primary Central Nervous System Post-Transplant Lymphoproliferative Disorder. Blood. 124(21). 1750–1750.
7.
Nicholas, Courtney, Jennifer Yang, Sara Peters, et al.. (2013). PRMT5 Is Upregulated in Malignant and Metastatic Melanoma and Regulates Expression of MITF and p27Kip1. PLoS ONE. 8(9). e74710–e74710. 71 indexed citations
8.
Karkhanis, Vrajesh, Sookil Tae, Fengting Yan, et al.. (2013). Protein Arginine Methyltransferase 5 (PRMT5) Inhibition Induces Lymphoma Cell Death through Reactivation of the Retinoblastoma Tumor Suppressor Pathway and Polycomb Repressor Complex 2 (PRC2) Silencing. Journal of Biological Chemistry. 288(49). 35534–35547. 73 indexed citations
9.
Alinari, Lapo, Bo Yu, Beth Christian, et al.. (2011). Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 117(17). 4530–4541. 66 indexed citations
10.
Yan, Fengting, Porsha Smith, Lapo Alinari, et al.. (2011). Developing a Novel Class of Drug to Inhibit Protein Arginine Methyltransferase 5 (PRMT5) Enzyme Dysregulation in Mantle Cell Lymphoma. Blood. 118(21). 595–595. 2 indexed citations
11.
Nicholas, Courtney, Fengting Yan, Sara Peters, et al.. (2011). Abstract 933: The expression of PRMT5 methyltransferase mediates cell survival and metastatic phenotype in malignant melanoma. Cancer Research. 71(8_Supplement). 933–933. 2 indexed citations
12.
Yan, Fengting, Xin Wu, Melissa Crawford, et al.. (2010). The search for an optimal DNA, RNA, and protein detection by in situ hybridization, immunohistochemistry, and solution-based methods. Methods. 52(4). 281–286. 17 indexed citations
13.
Nuovo, Gerard J., Xin Wu, Stefano Volinia, et al.. (2010). Strong Inverse Correlation Between MicroRNA-125b and Human Papillomavirus DNA in Productive Infection. Diagnostic Molecular Pathology. 19(3). 135–143. 54 indexed citations
14.
Yan, Fengting, Lapo Alinari, Mark Lustberg, et al.. (2010). Abstract 1584: Targeting protein arginine methyltransferase 5 (PRMT5) enzyme over expression in high grade astrocytomas. Cancer Research. 70(8_Supplement). 1584–1584. 1 indexed citations
15.
Liu, Qing, Lapo Alinari, Ching-Shih Chen, et al.. (2010). FTY720 Shows Promising In vitro and In vivo Preclinical Activity by Downmodulating Cyclin D1 and Phospho-Akt in Mantle Cell Lymphoma. Clinical Cancer Research. 16(12). 3182–3192. 47 indexed citations
16.
17.
Alinari, Lapo, Qing Liu, Ching‐Shih Chen, et al.. (2009). FTY720 Demonstrates Promising in-Vitro and in-Vivo Pre-Clinical Activity by Down-Modulation of Cyclin D1 and Pakt in Mantle Cell Lymphoma.. Blood. 114(22). 3728–3728. 1 indexed citations
18.
Alinari, Lapo, Erin Hertlein, David M. Goldenberg, et al.. (2008). Combination Anti-CD74 (Milatuzumab) and CD20 (Rituximab) Monoclonal Antibody Therapy Has in Vitro and in Vivo Activity in Mantle Cell Lymphoma. Blood. 112(11). 886–886. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stéphanie Sungalee Breakdown of academic impact, for papers by Zhongliang Ma Breakdown of academic impact, for papers by Angelique M. Leonhart Breakdown of academic impact, for papers by Francesca Pia Caruso Breakdown of academic impact, for papers by Kieren D. Marini Breakdown of academic impact, for papers by Elena Battistello Breakdown of academic impact, for papers by Helen Jiang Breakdown of academic impact, for papers by Danielle N. Yarde Breakdown of academic impact, for papers by Lilia Merida de Long Breakdown of academic impact, for papers by Salma Parvin
Rankless by CCL
2026